Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer

Journal of Clinical Oncology

Volumn 17, Issue 10, 1999, Pages 3270-3275

  Ilson, David H ^a   Saltz, Leonard ^a   Enzinger, Peter ^a   Huang, Ying ^a   Kornblith, Alice ^a   Gollub, Marc ^a   O'Reilly, Eileen ^a   Schwartz, Gary ^a   DeGroff, Julia ^a   Gonzalez, Gladys ^a   Kelsen, David P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BARIUM; CISPLATIN; DEXAMETHASONE; GRANISETRON; IRINOTECAN; LOPERAMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DYSPHAGIA; ESOPHAGOGRAPHY; ESOPHAGUS CANCER; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

EID: 0032887574     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.10.3270     Document Type: Article

References (18)

1. Landis SH, Murray T, Bolden S, et al: Cancer statistics, 1998. CA Cancer J Clin 48:6-29, 1998
2. Devesa SS, Blot WJ, Fraumeni JF Jr: Changing Patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83:2049-2053, 1998
3. Ilson D, Kelsen D: Systemic therapy in esophageal cancer, in Aisner J, Arriagada R, Green M, et al (eds): Comprehensive Textbook of Thoracic Oncology. Baltimore, MD, William & Wilkins, 1996, pp 630-649
4. Ilson DH, Bains M, Ginsberg RJ, et al: Neoadjuvant therapy of esophageal cancer. Surg Oncol Clin North Am 6:723-740, 1997
5. Hsiang YH, Liu LF: Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:722-726, 1988
6. Wall ME, Wani MC, Cook CE: Plant antitumor agents: 1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88:888-890, 1966
7. Kambe M, Wakui A, Nakao I, et al: A late phase II study of irinotecan (CPT-11) in patients with advanced gastric cancers. Proc Am Soc Clin Oncol 12:584, 1993 (abstr)
8. Shirao K, Shimada Y, Kondo H, et al: Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 15:921-927, 1997
9. Boku N, Ohtsu A, Shimada Y, et al: Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17:319-323, 1999
10. Saltz LB, Spriggs D, Schaaf LJ, et al: Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. J Clin Oncol 16:3858-3865, 1998
11. Miller AB, Hoogstraten B, Staquet M, et al: Reporting of cancer treatment. Cancer 47:207-214, 1981
12. Cella DF, Tulsky DS, Gray G: The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol 11:570-579, 1993
13. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinial trials in oncology. J Natl Cancer Inst 85:365-376, 1993
14. Knyrim K, Wagner HJ, Bethge N, et al: A controlled trial of an expansile metal stent for palliation of esophageal obstruction due to inoperable cancer. N Engl J Med 329:1302-1307, 1993
15. Gehan EA: The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13:346-353, 1961
16. Kaplan EL, Meier P: Nonparametric estimation for incomplete observation. J Am Stat Assoc 53:457-481, 1958
17. Spiridonidis CH, Laufman LR, Jones JJ, et al: A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma. Cancer 77:2070-2077, 1996
18. Lamond J, Wang M, Kinsella T, et al: Radiation lethality enhancement with 9-amino camptothecin: Comparison to other topoisomerase 1 inhibitors. Int J Radiat Oncol Biol Phys 36:369-376, 1996